Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suzetrigine effect on oral contraceptives PK
NCT06820307Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of suzetrigine in pain (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration of Drospirenone at Day 25, Area Under the Concentration Versus Time Curve From Time of Dosing Extrapolated to Infinity for Drospirenone at Day 25 and 7 more. Started Feb 2025; status: completed.
02
Drugs
suzetrigine
03
Conditions
pain
Beyond the preview
Go deeper on NCT06820307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06820307.